CI — Cigna Corporation

Analyst positioning is bullish (28 Buy/11 Hold, average target ~$338), and the July 30 Q2 beat plus raised guidance support that. But price action is not confirming: RSI is 47, price is below the 50-day and 200-day SMAs, and PBM/MLR overhangs keep buyers from chasing. The market seems to agree Cigna is cheap, but it is waiting for a cleaner catalyst.

Revenue growth is decelerating from the post-acquisition spike: YoY revenue growth was 28.4% in Q4 2024, about 14% in Q1 2025, 10-11% in mid-2025, and 6.6% in Q2 2026. That is still positive growth, but the pace has normalized. Operating income has been range-bound between roughly $2.1B and $2.7B per quarter, and reported EPS is noisy due to one-offs ($4.64 in Q4 2025, $6.97 in Q3 2025, $6.29 in Q2 2026). The cleanest signal is adjusted EPS, which beat and prompted a raised FY26 minimum of $30.45, implying forward earnings are inflecting up even as reported revenue growth slows.

On every conventional multiple, Cigna is cheap. Trailing P/E is 11.45x versus its own 5-year average of 16.34x; trailing P/S is 0.26x versus 0.41x; PEG is 0.36; P/B is 1.72; dividend yield is 2.19%. Forward P/E on raised FY26 adjusted EPS guidance of $30.45 is roughly 9.1x at $277.67. TTM free cash flow of about $9.1B gives a ~12% FCF yield. This is not fair value; it is pricing in meaningful regulatory/operating deterioration that has not yet shown up in the cash flows.

At $277.67, the market is applying only ~9.1x to FY26 adjusted EPS of $30.45 and ~11.45x to trailing GAAP EPS of $24.31. The consensus target of ~$338 merely assumes ~11.1x forward EPS, still well below the 5-year average. My own fair-value exercise, at 12x forward EPS, yields ~$365. So the stock is not pricing in even a modest re-rating. If management hits the raised guide and PBM reform stays headline risk rather than an earnings-destroying outcome, Cigna should grind toward or above consensus. If medical costs spike or PBM economics break, the current multiple is justified.

As of 2026-08-27, RSI was 47.04, which is neutral rather than oversold or overbought. Price sat just 0.03% below its 20-day SMA, 2.05% below its 50-day SMA, and 0.54% below its 200-day SMA, putting CI in a tight range within a 52-week band of $239.51-$315.47. There is no confirmed breakout or momentum signal. A close above the 50-day SMA would be a more constructive entry trigger; otherwise the stock is range-bound.

• PBM regulatory scrutiny: federal and state efforts to regulate pharmacy benefit manager rebates and pricing remain an overhang on Evernorth's multiple.
• Medical cost trend and MLR pressure: managed-care investors are sensitive to utilization trends, especially if commercial or government-book utilization rises.
• Interest rates: easing yields modestly relieve pressure on yield-sensitive insurers and support Cigna's buyback-funded EPS model.
• Employer/benefits selling season: 2027 PBM and health plan bids determine retention and new wins, with competition from CVS/Optum and others.
• Vertical integration and industry disruption: CVS, UnitedHealth, and Amazon pushing further into care and pharmacy could pressure PBM economics over time.

• Q3 2026 earnings, historically late October/early November 2026, with updated medical cost trends and confirmation of FY26 adjusted EPS above $30.45.
• 2027 selling season results: PBM/employer group wins and retention for Cigna Healthcare and Evernorth.
• Progress on Evernorth automation/AI efficiency initiatives and any large new client signings.
• Continued aggressive share repurchases and dividend increases, which compound EPS.
• Any clarity or resolution on PBM reform that removes the headline regulatory discount.

• PBM legislation or regulation that eliminates rebate-based economics or caps pharmacy reimbursements.
• Utilization/MLR upside: higher-than-expected medical costs could force guidance down.
• Customer or client loss: a major health plan or large employer leaving Evernorth would hit high-margin service revenue.
• Leverage and negative working capital: debt/equity of 0.75 and current ratio of 0.85 are typical for managed care but leave limited cushion if cash generation dips.
• Litigation or regulatory action specific to PBM practices and pricing transparency.

Cigna is a cheap, cash-generative managed-care and PBM business with a real regulatory cloud. The bear case needs PBM economics to break or medical costs to spike; the bull case needs only continued execution, and at roughly 9.1x forward earnings the downside appears protected by buybacks and free cash flow. That argues for neutral-to-positive, but not a high-conviction bullish call until the overhang demonstrably clears. This is analysis, not personalized financial advice.

I applied a 12.0x forward P/E to Cigna's raised FY2026 adjusted EPS guidance of $30.45. That multiple is a clear discount to the company's own 5-year average P/E of 16.34x but above the current ~9.1x forward multiple, reflecting the PBM/regulatory overhang while crediting the beat-and-raise, buyback-driven EPS growth, and robust FCF generation. The result is $365.40.